Covance Elects Bradley T. Sheares to Company's Board of Directors
PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:
CVD) today announced that it has elected Bradley T. Sheares, Ph. D., to its
Board of Directors.
Dr. Sheares is former chief executive officer and member of the Board of
Directors of Reliant Pharmaceuticals, Inc., a pharmaceutical company that
marketed a portfolio of branded cardiovascular medicines. Prior to joining
Reliant, he was president of the U.S. Human Health division of Merck and Co.,
Inc., where he led commercial efforts in the United States for the company's
portfolio of prescription medicines for the treatment of chronic and acute
diseases. In addition to this role, Dr. Sheares was a member of Merck's
management committee, which was responsible for formulating global business
strategies, managing operations and setting corporate policies. He joined
Merck in 1987 as research fellow in the Merck Research Laboratories, and he
held positions of increasing responsibility in Merck until his departure in
"We are very pleased to welcome Dr. Sheares to our Board of Directors. His
scientific background, academic achievements and extensive experience in
bringing new medicines to the market will strengthen Covance's ability to
provide innovative drug development solutions to our clients, " said Joe
Herring, Covance chairman and CEO. "We look forward to leveraging Dr. Sheares'
outstanding record of leadership and management, as well as his focus on
recruiting top talent, to help our company sustain its leadership position in
the industry and continue to provide value to our shareholders and employees."
"Covance has been at the forefront of creating innovative models of
outsourcing," said Dr. Sheares. "I am thrilled at the opportunity to be part
of such an accomplished group of individuals and to leverage my health care
experience in enhancing the company's ability to deliver high-quality service
and integrated solutions to its clients."
Dr. Sheares also serves on the Board of Directors of Honeywell
International, a diversified technology and manufacturing company, and The
Progressive Corporation, one of the nation's largest insurance holding
companies. In addition, he serves on the Board of Trustees of Spelman College
and is a member of the College of Physicians of Philadelphia, the Abington
Friends School Committee, the Scientific Advisory Council for Montclair State
University, and the Executive Leadership Council. He is the former chair of
the Board of Directors of the National Pharmaceutical Council, which focuses
on broadly communicating the economic, clinical and societal value of
Dr. Sheares graduated summa cum laude with a bachelor's degree in
chemistry from Fisk University and earned his doctorate in biochemistry from
Purdue University. He completed his postdoctoral training as a Lucille P.
Markey Scholar and NIH Research Fellow at the Massachusetts Institute of
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.7 billion, global operations in more than 20
countries, and more than 9,600 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.